Insurers Say They ‘Can’t Afford’ Ozempic and Zepbound. What the Data on Healthier Patients and Cost Savings Actually Shows.

Update, October 15, 2026: Several things have changed since this article was first published. TrumpRx.gov now lists self-pay prices of $149 a month for the Wegovy pill, $199 for the Wegovy pen, $199 for Ozempic and $299 for Zepbound. The FDA approved orforglipron, an oral GLP-1 from Eli Lilly sold as Foundayo, for adult obesity (Healio, April 1, 2026), with the lowest dose at $149 a month through LillyDirect. Medicare began a GLP-1 Bridge demonstration on July 1, 2026 that charges $50 a month, runs outside Part D (the standard Medicare drug benefit), and requires prior authorization, according to CMS; it is scheduled to run through December 31, 2027. CVS Caremark returned Zepbound to its commercial formularies on October 1, 2026. We also corrected the Aon figures below, which had mixed diabetes and weight-loss results and omitted the adherence qualifier on the heart figure.

In the first half of 2026, a growing number of employers and insurers announced they were scaling back or ending coverage for GLP-1 medications like Zepbound and Wegovy when used for weight loss. HeadLines framed it as simple arithmetic: these drugs cost too much, and plans could no longer afford them. The picture is more complicated, and the emerging data on what happens to patients’ health and downstream medical costs when people stay on these medications adds context that the "can’t afford it" narrative often leaves out.

Plans Are Cutting Weight-Loss Coverage

Across 2025 and into 2026, multiple major players restricted access specifically for the obesity indication. Blue Cross Blue Shield of Massachusetts ended standard coverage of GLP-1 weight-loss drugs in January 2026, though employers can buy it back for a higher charge. CVS Caremark dropped Zepbound from its standard formularies on July 1, 2025, then reversed course: Fox 35 Orlando reported in May 2026 that Zepbound returns as a preferred drug on October 1, 2026, though employers still decide whether to cover it. California’s Medi-Cal program stopped covering Wegovy and Zepbound for weight loss for adults on January 1, 2026, while keeping coverage for Type 2 diabetes, other medical need, and patients under 21. New Hampshire, Pennsylvania, and South Carolina also ended adult obesity coverage that day, and MedBound Times, citing a KFF survey, counted 16 state Medicaid programs still covering these drugs as of October 1.

Employer surveys show the same drift. A Business Group on Health survey of 127 employers covering 8.7 million people, reported by SHRM on September 1, 2026, found that coverage for obesity treatment fell from 72 percent of employers in 2025 to 60 percent in 2026. Another 14 percent had dropped it or planned to by 2027, up from 10 percent, and Starbucks said it would end weight-loss coverage in October. For many patients, the change arrived via prior authorization denials or outright exclusion notices rather than gradual tightening.

Budget Pressure on Insurer Spreadsheets

The dominant explanation from benefits managers and insurers is straightforward budget pressure. GLP-1 medications moved from niche to top-line cost driver with extraordinary speed. A 2026 report from the benefits vendor Espresa put GLP-1s at 10.5 percent of employer prescription claims, up from 6.9 percent in 2023, with spending per member per month rising from $11 to $24. Business Group on Health reports that pharmacy accounts for about a quarter of employer health spending. For self-insured employers (companies that pay claims themselves), the combination of high drug prices and rapid uptake among eligible employees created immediate and visible hits to pharmacy budgets.

Rebates and discounts soften the sticker price, but the sheer volume of prescriptions made these drugs impossible to ignore in annual renewals.

Claims Data on Long-Term Users

Clinical trials have long shown that GLP-1 receptor agonists produce substantial weight loss and meaningful reductions in cardiovascular risk markers. Claims data now offers a first look at the economic side, with an important limit on how far it can be trusted.

In a January 13, 2026 press release, the benefits consultant Aon described a proprietary analysis of medical and pharmacy claims from more than 50 million commercial lives, including 192,000 GLP-1 users, between July 2022 and March 2025. This is a company announcement, and the release does not say it was peer reviewed or published in a journal. It also leaves out the study design, the matching method, confidence intervals and limitations, and Aon sells related analytics. Read the figures as associated with GLP-1 use, with causation unproven:

3 to 7 ptsHow much slower medical costs grew among weight-loss GLP-1 users: 3 points at 18 months, 7 points with consistent use, per Aon’s unreviewed January 2026 press release. For diabetes users it reported 6 points at 30 months and 9 points at 80 percent adherence or better.

The same release reported that female GLP-1 users had about 50 percent lower ovarian cancer incidence and about 14 percent lower breast cancer incidence than female non-users. It gave no adherence level for those two figures and did not describe how the groups were matched for cancer. For heart disease, hospitalizations for major adverse cardiovascular events were lower than among matched non-users, by 47 percent in women and 26 percent in men, among people with adherence of 80 percent or better. People who stick with a drug tend to differ from those who stop in ways claims data cannot fully capture, so none of these numbers show what the drugs did.

The heart figures resemble findings from large heart-outcome trials of semaglutide and tirzepatide, which gives them some plausibility. The cost figures cover 18 months for weight loss and 30 months for diabetes, a window that many large self-insured employers can actually measure.

Reasons Plans Keep Cutting Despite the Savings

Plans still have reasons to walk away. Timing is the biggest.

• Front-end costs, back-end savings. The drug expense hits immediately and every month. Avoided heart attacks and diabetes complications accrue over years. Many employer plan horizons and employee tenure windows are shorter than the payback period.
• Adherence is everything and it’s hard. Persistence on GLP-1s is often well below the high-adherence thresholds where the strongest cost-growth reductions appear. Prime Therapeutics, a pharmacy benefit manager, found in July 2024 claims data that 71 percent of new weight-loss users had stopped by one year and 85 percent by two years. That predates the pills and the price cuts, so today’s rate may differ.
• Workforce turnover. A self-insured employer that pays for two years of therapy may never see the downstream savings if the employee moves to a different plan.
• Prices are still high for the savings seen so far. Independent cost-effectiveness modeling published in JAMA Health Forum in 2025 found that tirzepatide and semaglutide generate substantial lifetime health gains but carry a cost of $197,023 (tirzepatide) and $467,676 (semaglutide) for each extra year of healthy life gained, well above the roughly $100,000 usually treated as good value.

A Patient Checklist for the Coverage Maze

Prices and rules shifted this year, so a plan that covered a drug last January may not cover it now. These steps follow the facts above.

• Ask the plan about the drug itself. Is it on the formulary (the plan’s list of covered drugs), which tier, and is weight-loss coverage excluded? Business Group on Health found 40 percent of surveyed employers do not cover obesity treatment.
• Get prior-authorization criteria in writing. Typical tests are BMI and related conditions. Medicare’s new program shows one pattern: a BMI of 35 or higher, or 30 or higher with heart failure, uncontrolled high blood pressure or chronic kidney disease, or 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease (CBS News summary).
• Match the drug to the diagnosis. Diabetes versions often stay covered while Wegovy and Zepbound are labeled for obesity. In January 2026 the FDA asked the makers of Wegovy, Zepbound and Saxenda to remove the suicidal ideation warning from their labels after a review, so check that you are reading a current label.
• Ask when coverage ends. Employers decide annually, so a drug that is covered now may not be at renewal.
• Compare cash prices with your copay. Listed self-pay prices start at $149 and run to $299 a month (see the update above), and cash payments may not count toward your deductible.
• Plan the long run before you start. The 2026 Obesity Society and Obesity Medicine Association guideline, as summarized by Guideline Central, favors continuing medication during maintenance over stopping. Talk with your prescriber before changing a dose or quitting.
• If you are on Medicare, check the new program. Medicare.gov/glp1bridge and 1-800-MEDICARE can tell you whether you qualify.

The Coverage Outlook

The coverage reversals come from how American healthcare financing handles expensive chronic-disease drugs: a focus on near-term budget impact and little ability to capture long-term returns across different payers.

Long-term users show up in large claims datasets with fewer medical resources used over time. The challenge is aligning the payment model with that possibility through outcomes-based contracts, longer-term risk sharing, or pricing that reflects demonstrated value.

For now, the "can’t afford it" headlines capture a genuine short-term constraint for many plans. The fuller story is that some patients are getting healthier on these drugs and the claims data hint at lower medical cost trajectories, but only where adherence is high and the time horizon is long, and the best of that evidence is not yet independently tested.

The same question, asked of a different corner of medicine: New Dental Tools: Longer-Lasting Care or a More Expensive Tool Belt?.

This article is health information, not medical advice.

Editor written. AI used for spelling and grammar only.